Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below.
Eli Lilly (NYSE: LLY) is reportedly in talks to acquire cancer biotech Kelonia Therapeutics in a deal that could be worth more than $7 billion (1).
The proposed acquisition would give Lilly access to Kelonia’s experimental gene delivery platform, designed to improve the delivery of therapies such as CAR-T within the body. It’s a fast-growing area of cancer research and a marked departure from Lilly’s reliance on weight-loss medications, such as semaglutide.
Under the reported structure, the deal could be worth up to $7 billion, including $3.25 billion paid upfront, with additional milestone-based payments tied to “clinical, regulatory and commercial milestones.”
The move would also deepen Lilly’s involvement in oncology — the branch of medicine focused on the treatment of cancer — one of the most competitive and lucrative sides of the pharmaceutical industry. In 2025, the oncology drugs market was valued at $256.46 billion, with projections of $697.59 billion by 2034, according to Fortune Business Insights (2).
Cancer remains one of the leading causes of death in the U.S., with over 9 million new cancer cases and 3 million cancer-related deaths recorded from 2018 to 2022 (3).
Kelonia, which has remained privately held, was valued at just over $100 million as recently as 2022 (4). If the deal goes through at a multi-billion-dollar valuation, it would represent a staggering jump for early investors.
While Kelonia itself remains out of reach for public investors, deals like this can still make an impact on the market.
When giants like Eli Lilly move to acquire emerging technologies, it’s a signal of where capital (and innovation) could be heading next. Although not a sure thing, in this case, it points squarely toward advanced cancer treatments and gene therapies.
Major acquisitions can lift valuations across an entire sector. So while the earliest stage of growth tends to happen behind closed doors, the broader trend won’t stay hidden long.
For investors paying attention, that can create some opportunities.
Read More: Robert Kiyosaki warned of a ‘Greater Depression’ — with millions of Americans going poor. Was he right?
In 2023, Pfizer (NYSE: PFE) completed its $43 billion acquisition of Seagen, a biotech firm specializing in targeted cancer therapies (5). It was one of the largest deals in the sector’s history and signaled a broader push to expand oncological pipelines.
Albert Bourla, Pfizer CEO, reportedly said during a conference call at the time, “We are not buying the golden eggs. We are acquiring the goose that is laying the golden eggs.”
Bourla’s instincts were correct. Following the initial reports of the deal, Seagen’s stock rose nearly 11% (6). In the months following the deal, several publicly traded biotech firms working on similar treatments saw new interest and confidence from investors (7).
While not every company will follow the same trajectory or be as successful, the Pfizer deal helped direct a large amount of capital into the space.
At a smaller scale, the same dynamic is playing out here in Lilly’s pursuit of Kelonia: A large, well-known, well-capitalized player identifying a promising area of innovation and, in doing so, putting a spotlight on the broader field.
So how can retail investors also jump in on this trend?
Retail investors might be gatekept from companies like Kelonia directly, but they can still invest in the broader trend. One way to do that is to gain exposure to publicly traded biotech and healthcare companies, particularly those operating in oncology. With that said, it’s important to remember that the real gains typically come when a product is pushed to market after the research and development period ends.
Another is to invest in the broader ecosystem surrounding these breakthroughs, sometimes referred to as a pick-and-shovel strategy, where you back the companies that supply tools, platforms or infrastructure to the firms driving innovation (8).
Consider Sofi Invest to make that process more accessible. Its easy-to-use DIY investing platform lets you buy stocks and ETFs from biotech and pharmaceutical markets with no commission fees and no account minimums.
Sofi is designed for beginners and experienced investors. It offers real-time market data, curated insights and tools to help users make more informed decisions about where they put their money.
Plus, for a limited time, new users can get up to $1,000 in stock when they fund an account.
For investors looking to act on trends already playing out in public markets, that kind of access can be a practical starting point.
But for those more focused on identifying opportunities before they become obvious, there are other approaches worth considering.
Getting exposure to a market trend once it hits is one thing. Spotting where capital is flowing before it becomes obvious is another.
That’s where research-driven platforms like Moby come in.
In four years, and across almost 400 stock picks, their recommendations have beaten the S&P 500 by almost 12% on average. They also offer a 30-day money-back guarantee.
Moby’s team spends hundreds of hours sifting through financial news and market data, including trends in sectors like biotech, to provide you with digestible stock and crypto reports delivered straight to you. Their research keeps you up-to-the-minute on market shifts and can help you reduce the guesswork behind choosing stocks and ETFs.
For investors trying to identify the next wave — whether that’s in cancer therapies, AI, or another emerging space — that kind of insight takes the guesswork out and highlights opportunities earlier.
Plus, if you’re a beginner, their reports are easy to understand so that you can become a smarter investor in just five minutes.
Identifying trends like the surge in oncology is one thing. Building a balanced and profitable portfolio around them is another.
For investors, that’s where a financial advisor can make all the difference.
That’s where Advisor.com can come in. The platform connects users with vetted financial professionals who can help assess their portfolios and build a strategy that includes high-growth sectors like biotech, without overconcentrating in a single trend.
Just enter a few details about your finances and goals, and Advisor.com’s AI-powered matching tool will connect you with a qualified expert best suited for your needs.
Finding the right advisor isn’t always easy — there’s no one-size-fits-all solution. That’s why Advisor.com lets you set up a free initial consultation, with no obligation to hire, to see if they’re the right fit for you.
Rather than trying to pick the next Kelonia, an advisor can help you build diversified exposure across the broader healthcare and innovation landscape.
For investors who want guidance, structure or simply a second opinion, it’s a way to stay involved in opportunities like this without having to figure everything out alone.
Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
We rely only on vetted sources and credible third-party reporting. For details, see our ethics and guidelines.
Reuters (1); Fortune Business Insights (2); Centers for Disease Control and Prevention (3); The Wall Street Journal (4); Fierce Pharma (5); Business Insider (6); RBC Capital Markets (7); Investopedia (8)
This article provides information only and should not be construed as advice. It is provided without warranty of any kind.
